Ki-Young Son
Fortune : 3 M $ au 31/03/2026
Fortune : 3 M $ au 31/03/2026
Ki-Young Son has been Chairman & Chief Executive Officer at ENZYCHEM LIFESCIENCES Corp.
since 2012.
Mr. Son has been Chairman at Bridget Lifesciences Corp.
since 2003.
Son completed undergraduate and graduate degrees at Korea University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/05/2026 | 4 069 430 ( 4,78% ) | 3 M $ | 31/03/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Directeur Général | 01/06/2012 |
Bridget Lifesciences Corp.
Bridget Lifesciences Corp. Financial ConglomeratesFinance Functions as an investment holding company | Président | 01/01/2003 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 3 |
|---|---|
Korea University
Korea University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ENZYCHEM LIFESCIENCES Corp.
ENZYCHEM LIFESCIENCES Corp. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Bridget Lifesciences Corp.
Bridget Lifesciences Corp. Financial ConglomeratesFinance Functions as an investment holding company | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national